Solid Biosciences Inc. filed a prospectus supplement to its universal shelf registration statement on Form S-3, authorizing the offer and sale of up to $200.0 million in shares of common stock under an Amended and Restated Sales Agreement with Jefferies LLC. This filing supersedes a prior prospectus supplement that had authorized up to $85.0 million; approximately $85.0 million has already been issued and sold under the previous authorization, which is now closed. The company operates in the biotechnology industry, focusing on gene therapy for inherited retinal diseases.

On June 10, 2026, stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 240,000,000 to 480,000,000. The company filed the Certificate of Amendment with the Secretary of State of Delaware on the same day. Other meeting outcomes included the election of Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan, the advisory ratification of Ilan Ganot as a Class I director, the ratification of PricewaterhouseCoopers LLP as independent auditor, and the approval of executive compensation. Solid Biosciences Inc. is a biotechnology company that develops genetic medicines for rare diseases.